NasdaqGS:NBIXBiotechs
Neurocrine Biosciences (NBIX) Is Up 5.1% After Peer-Reviewed Study Highlights INGREZZA’s Clinical Profile
On November 20, 2025, Neurocrine Biosciences announced the publication of a comprehensive peer-reviewed narrative review consolidating over a decade of clinical research on the FDA-approved VMAT2 inhibitors INGREZZA and deutetrabenazine for tardive dyskinesia.
The review highlights key differences in pharmacologic, dosing, and clinical profiles between the two treatments, providing practitioners with updated evidence derived from double-blind, placebo-controlled trials and long-term...